Kennewick, WA — September 3, 2025 — Leads & Copy — Vivos Inc. (OTCQB: RDGL) has announced the successful validation of a new electron beam (E-Beam) sterilization process for its hydrogel. The validation was carried out under ISO 11137 by an international medical device accredited organization. This marks the culmination of nearly a year of testing, made viable by the unique characteristics of Vivos’ hydrogel, according to the company.
The E-Beam sterilization process is more reliable than the current filtration process, achieving a sterility assurance level of 10-6. This rigorous sterility level minimizes infection risk, ensuring patient safety. The process is also more cost-effective, improves production yield, and enhances scalability.
The ability to efficiently produce and distribute sterile hydrogel and PrecisionGel for therapeutic agent dispersal worldwide supports Vivos’ strategic path toward broader market penetration. The process will also drive greater manufacturing efficiency for IsoPet®, the animal health therapy, enabling more consistent supply and cost-effective production to meet growing veterinary demand.
Michael K. Korenko, Sc.D., President & CEO of Vivos Inc., can be reached at MKorenko@RadioGel.com.
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
